Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 73,360 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.51, for a total value of $330,853.60. Following the completion of the sale, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at $3,029,750.35. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP traded down $0.01 during trading on Thursday, reaching $4.60. 360,793 shares of the stock traded hands, compared to its average volume of 241,456. Oramed Pharmaceuticals Inc. has a 52-week low of $1.98 and a 52-week high of $5.19. The company has a 50-day moving average of $4.08 and a 200-day moving average of $3.62. The stock has a market capitalization of $188.26 million, a P/E ratio of 1.78 and a beta of 1.21.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its position in shares of Oramed Pharmaceuticals by 2.7% during the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 3,909 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $63,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 7,738 shares in the last quarter. Hillsdale Investment Management Inc. bought a new position in Oramed Pharmaceuticals in the 1st quarter worth about $331,000. Finally, Kathmere Capital Management LLC purchased a new position in Oramed Pharmaceuticals during the 1st quarter valued at about $51,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.